The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Updated results of a phase Ib single-center study of pembrolizumab in combination with chemotherapy in patients with locally advanced or metastatic small cell/neuroendocrine cancers of the prostate and urothelium.
 
Arnold I. Chin
Honoraria - Intuitive Surgical
Consulting or Advisory Role - Johnson & Johnson/Janssen
Research Funding - Merck
 
Ann Ly
No Relationships to Disclose
 
Sara Rodriguez
No Relationships to Disclose
 
Ankush Sachdeva
No Relationships to Disclose
 
Nazy Zomorodian
No Relationships to Disclose
 
Hanwei Zhang
No Relationships to Disclose
 
Jiyoon Kim
No Relationships to Disclose
 
Gang Li
No Relationships to Disclose
 
Matthew Rettig
Leadership - Aravalent; Survalent
Stock and Other Ownership Interests - Oncovalent Therapeutics; Survalent
Consulting or Advisory Role - Ambrx; Amgen; Clovis Oncology; Inmune Bio; Roivant
Speakers' Bureau - Bayer; Johnson & Johnson
Research Funding - Johnson & Johnson (Inst); Medivation/Astellas (Inst); Novartis (Inst); Progenics
Patents, Royalties, Other Intellectual Property - I am a co-inventor on a patent for novel inhibitors of the N-terminal domain of the AR. There are NO commercial partnerships as of yet.
Travel, Accommodations, Expenses - Johnson & Johnson
 
Sandy Liu
Honoraria - Eisai; EMD Serono; Exelixis; Merck; Seagen; Seagen
Consulting or Advisory Role - Exelixis; Exelixis; Seagen; Seagen; Seagen
Speakers' Bureau - EMD Serono; Exelixis; Exelixis; Seagen
 
Alexandra Drakaki
Employment - ATHOS THERAPEUTICS (I); ATTICA SCIENCES (I); Dyania Health (I)
Leadership - ATHOS THERAPEUTICS (I); ATTICA SCIENCES (I)
Stock and Other Ownership Interests - Alimera Sciences (I); Athos Therapeutics (I); ATTICA SCIENCES; Dyania Health (I); Kyn therapeutics (I); Moderna Therapeutics (I); PROTEAS BIOANALYTICS (I); Urogen pharma (I)
Consulting or Advisory Role - AstraZeneca; AVEO; Bristol-Myers Squibb; DYANIA HEALTH; Exelixis; Janssen; Merck; PACT Pharma; RADMETRIX; Roche/Genentech; Seagen
Research Funding - AstraZeneca (Inst); BMS (Inst); Genentech/Roche (Inst); Immunomedics/Gilead (Inst); Infinity Pharmaceuticals (Inst); Jounce Therapeutics (Inst); Kite/Gilead; Merck Sharp & Dohme (Inst); Seattle Genetics/Astellas (Inst)
Patents, Royalties, Other Intellectual Property - My significant other has several patents with UCLA, Harvard Medical School, Athos Therapeutics, Proteas Bioanalytics and ATTICA Sciences (I)
Travel, Accommodations, Expenses - AstraZeneca; Lilly; Seagen